Diego Ferone
www.dimi.unige.it
0000-0002-1410-6143
University of Genoa
264 papers found
Refreshing results…
Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly
Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment
Acute administration of hexarelin stimulates GH secretion during day and night in normal men
Effect of Different Dopaminergic Agents in the Treatment of Acromegaly
O-054. Lymphocyte subset pattern (LSP) in acromegaly
Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly
Effect of Growth Hormone on Cardiac Function
Cardiovascular aspects in acromegaly: Effects of treatment
Vasopressin levels in Cushing's disease: inferior petrosal sinus assay, response to corticotrophin-releasing hormone and comparison with patients without Cushing's disease
Prediction of efficacy of octreotide therapy in patients with acromegaly.
Tumor Necrosis Factor-Alpha Increases after Corticotropin-Releasing Hormone Administration in Cushing’s Disease
Corticotropin Releasing Hormone Administration Increases Alpha-Melanocyte-Stimulating Hormone Levels in the Inferior Petrosal Sinuses in a Subset of Patients with Cushing’s Disease
Acute and chronic effects of octreotide on thyroid axis in growth hormone-secreting and clinically non-functioning pituitary adenomas
Technetium-99m pentavalent dimercaptosuccinic acid imaging in patients with pituitary adenomas
CV 205-502 treatment in therapy-resistant acromegalic patients
Comparison among Different Dopamine-Agonists of New Formulation in the Clinical Management of Macroprolactinomas
Impaired luteinizing hormone responsiveness to gonadotropin-releasing hormone in the inferior petrosal sinuses of hyperprolactinemic patients
Hypothalamic-Pituitary-Adrenal Axis in Neuropsychiatric Disorders
Effect of corticotrophin-releasing hormone administration on growth hormone levels in acromegaly: in vivo and in vitro studies
Positive response to compound CV 205–502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine
Missing publications? Search for publications with a matching author name.